drugset
drugset / Trial / NCT04915950

A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis

NCT04915950 ↗

Phase 2 Terminated 13 enrolled Pfizer Arena is a wholly owned subsidiary of Pfizer · collab
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to determine whether oral temanogrel improves digital blood flow in participants with Raynaud's phenomenon secondary to systemic sclerosis (SSc-RP) as a potential safe and effective treatment for symptoms associated with SSc-RP.

Timeline

Start
2021-11-03
Primary completion
2022-09-02
Completion
2022-09-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Temanogrel Small molecule — Oral

Indications

systemic sclerosis